Prognostic Significance of MicroRNA-101 in Solid Tumor: A Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Jul 26

PMID 28742860

Citations 4

Authors

Xianxiong Ma

Jie Bai

Gengchen Xie

Yulin Liu

Xiaoming Shuai

Kaixiong Tao

Affiliations

Soon will be listed here.

Abstract

MicroRNA-101 has been reported as an important factor in carcinogenesis of several malignant tumors. However, its actual role in prognosis among solid malignancies remains unclear. Accordingly, we performed this meta-analysis aiming to identify prognostic significance of miR-101 in solid tumor. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) or disease-free survival (DFS)/metastasis-free survival (MFS)/progression-free survival (PFS)/relapse-free survival (RFS)/time-to progression (TTP) were estimated with random effects or fixed effects models on the basis of heterogeneity. Subgroup analysis, sensitive analysis and meta-regression analysis were also conducted to clarify the possible confounding factors and investigate the source of heterogeneity. Publication bias was evaluated by using Begg's and Egger's tests. A total of 21 studies containing 3753 cases were selected into our quantitative analysis via electronic database search. A lower expression of miR-101 was significantly associated with worse OS (HR = 0.66, 95%CI [0.52-0.85], P = 0.001) and PFS (HR = 0.70, 95%CI [0.51-0.95], P = 0.023) in patients with solid tumor. The under-expression of miRNA-101 is a credible indicator of poorer prognosis in several of solid malignancies.

Citing Articles

Prognostic significance of microRNA miR-24 in cancers: a meta-analysis.

Liu R, Kong W, Zheng S, Yu C, Yu Y, Xu Y Bioengineered. 2021; 12(1):450-460.

PMID: 33550881 PMC: 8291878. DOI: 10.1080/21655979.2021.1875662.

Prognostic Value and Clinicopathological Features of MicroRNA-206 in Various Cancers: A Meta-Analysis.

Liu R, Zheng S, Peng S, Yu Y, Fang J, Tan S Biomed Res Int. 2020; 2020:2159704.

PMID: 33145343 PMC: 7596429. DOI: 10.1155/2020/2159704.

Focused screening reveals functional effects of microRNAs differentially expressed in colorectal cancer.

Sastre D, Baiochi J, Lima I, de Souza F, Corveloni A, Hassib Thome C BMC Cancer. 2019; 19(1):1239.

PMID: 31864341 PMC: 6925883. DOI: 10.1186/s12885-019-6468-5.

Low Serum Levels of miR-101 Are Associated with Poor Prognosis of Colorectal Cancer Patients After Curative Resection.

He D, Yue Z, Li G, Chen L, Feng H, Sun J Med Sci Monit. 2018; 24:7475-7481.

PMID: 30341274 PMC: 6204656. DOI: 10.12659/MSM.909768.

References

Wu B, Lei D, Wang L, Yang X, Jia S, Yang Z . MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1. Am J Cancer Res. 2016; 6(6):1396-407. PMC: 4937741. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Chakravarthi B, Goswami M, Pathi S, Robinson A, Cieslik M, Chandrashekar D . MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. Oncogene. 2016; 35(49):6330-6340. PMC: 5140777. DOI: 10.1038/onc.2016.164. View

Schee K, Boye K, Abrahamsen T, Fodstad O, Flatmark K . Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012; 12:505. PMC: 3519622. DOI: 10.1186/1471-2407-12-505. View

Slattery M, Herrick J, Pellatt D, Mullany L, Stevens J, Wolff E . Site-specific associations between miRNA expression and survival in colorectal cancer cases. Oncotarget. 2016; 7(37):60193-60205. PMC: 5312378. DOI: 10.18632/oncotarget.11173. View

Zhang S, Yuan W, Tang W, Xu C, Ma J . [Expression of microRNA-100 and its relation with prognosis of colorectal cancer]. Zhonghua Zhong Liu Za Zhi. 2015; 37(8):603-8. View

Bao R, Shu Y, Hu Y, Wang X, Zhang F, Liang H . miR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinoma. Oncotarget. 2016; 7(16):22339-54. PMC: 5008364. DOI: 10.18632/oncotarget.7970. View

Li M, Tian L, Ren H, Chen X, Wang Y, Ge J . MicroRNA-101 is a potential prognostic indicator of laryngeal squamous cell carcinoma and modulates CDK8. J Transl Med. 2015; 13:271. PMC: 4545549. DOI: 10.1186/s12967-015-0626-6. View

Liu H, Xing A, Chen X, Ma R, Wang Y, Shi D . MicroRNA-27b, microRNA-101 and microRNA-128 inhibit angiogenesis by down-regulating vascular endothelial growth factor C expression in gastric cancers. Oncotarget. 2015; 6(35):37458-70. PMC: 4741941. DOI: 10.18632/oncotarget.6059. View

10.

Cochran W . The comparison of percentages in matched samples. Biometrika. 1950; 37(3-4):256-66. View

11.

Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T . Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci. 2009; 101(1):241-9. PMC: 11159282. DOI: 10.1111/j.1349-7006.2009.01385.x. View

12.

Liu C, Sun Y, She X, Tu C, Cheng X, Wang L . CASC2c as an unfavorable prognosis factor interacts with miR-101 to mediate astrocytoma tumorigenesis. Cell Death Dis. 2017; 8(3):e2639. PMC: 5386525. DOI: 10.1038/cddis.2017.11. View

13.

Yamamoto H, Mori M . MicroRNAs as Therapeutic Targets and Colorectal Cancer Therapeutics. Adv Exp Med Biol. 2016; 937:239-47. DOI: 10.1007/978-3-319-42059-2_13. View

14.

Zheng F, Liao Y, Cai M, Liu T, Chen S, Wu P . Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. PLoS Genet. 2015; 11(2):e1004873. PMC: 4334495. DOI: 10.1371/journal.pgen.1004873. View

15.

Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao Y . MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance. Med Oncol. 2011; 29(3):1681-6. DOI: 10.1007/s12032-011-0085-8. View

16.

Thomson D, Dinger M . Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016; 17(5):272-83. DOI: 10.1038/nrg.2016.20. View

17.

Jansen M, Reijm E, Sieuwerts A, Ruigrok-Ritstier K, Look M, Rodriguez-Gonzalez F . High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat. 2011; 133(3):937-47. PMC: 3387494. DOI: 10.1007/s10549-011-1877-4. View

18.

Lv X, Li J, Yang B . Clinical effects of miR-101 on prognosis of hepatocellular carcinoma and carcinogenic mechanism of anti-miR-101. Oncol Rep. 2016; 36(4):2184-92. DOI: 10.3892/or.2016.4980. View

19.

Mangalhara K, Manvati S, Saini S, Ponnusamy K, Agarwal G, Abraham S . ERK2-ZEB1-miR-101-1 axis contributes to epithelial-mesenchymal transition and cell migration in cancer. Cancer Lett. 2017; 391:59-73. DOI: 10.1016/j.canlet.2017.01.016. View

20.

Li X, Shi Y, Yin Z, Xue X, Zhou B . An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma. J Transl Med. 2014; 12:159. PMC: 4062505. DOI: 10.1186/1479-5876-12-159. View